UBS lowered the firm’s price target on Bruker (BRKR) to $45 from $57 and keeps a Neutral rating on the shares. Bruker guided lower amid U.S. research funding and tariffs, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- Bruker price target lowered to $48 from $57 at Stifel
- Bruker price target lowered to $46 from $50 at Barclays
- Bruker: Resilient Performance and Strategic Positioning Amidst 2025 Challenges
- Bruker Corporation Reports Strong Q1 2025 Revenue Growth
- Bruker Hold Rating: Balancing Optimism and Caution Amidst Uncertainties